Jiangsu Hengrui Pharmaceuticals (600276.SH): The clinical trial application for Fruquichuzhu monoclonal antibody injection has been approved.

13/02/2025

GMT Eight

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the approval notification from the National Medical Products Administration for the clinical trials of the injection of Fuzhao Chi Zhu monoclonal antibody. The company will soon start the clinical trials. Fuzhao Chi Zhu monoclonal antibody injection is a recombinant humanized monoclonal antibody that targets human IL-17A, developed by the company, intended for the treatment of autoimmune diseases related to the IL-17 pathway.

Shaanxi Sirui Advanced Materials (688102.SH) reported a net profit of 1.17 billion yuan in 2024, representing a year-on-year increase of 19.21%.

TATA HEALTH(01255): No definitive transaction documents have been entered into for the possible sale of pledged shares. The trading halt will continue.

Contact: contact@gmteight.com

Jiangsu Hengrui Pharmaceuticals (600276.SH): The clinical trial application for Fruquichuzhu monoclonal antibody injection has been approved.

RECOMMEND

One of the controlling shareholders of Qingdao Choho Industrial (003033.SZ) plans to reduce their stake by no more than 3%.

Shanghai Smart Control (001266.SZ): Contain Tai Investment plans to reduce its holdings by no more than 6380 shares.

Two shareholders of Cosonic Intelligent Technologies (300793.SZ) plan to collectively reduce their holdings by no more than 2.27%.